A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab
Journal of Obstetrics and Gynaecology Research · 2025
DOI: 10.1111/jog.16182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Shintaro Yanazume und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Antibodies, Monoclonal, Humanized, Quinolines, Phenylurea Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
To identify prognostic biomarkers that could predict how well patients will respond to lenvatinib/pembrolizumab (LEN/PEM). The utility of certain inflammatory biomarkers in endometrial liquid‐based cytology (LBC) or peripheral blood samples, such as neutrophil counts, lymphocyte counts, and neutrophil‐to‐lymphocyte ratio (NLR) were explored.
Methods
The study included 25 patients with advanced or recurrent endometrial cancer who had received LEN/PEM between August 2018 and March 2024. Predictors for overall response (OR), disease control, and progression‐free survival, based on neutrophil/lymphocyte counts, NLR scores of the endometrial LBC prior to initial treatment, and peripheral blood prior to initial treatment and prior to LEM/PEM treatment were compared using a receiver operating characteristic curve. Significant predictors were evaluated using the log‐rank test, and multivariate analysis.
Results
Although neutrophil counts and NLR score in endometrial LBC prior to initial treatment were better effective predictors for OR, the most accurate predictor of a progression‐free status was NLR score in peripheral blood prior to LEM/PEM (0.722, 95% CI: 0.45–0.99, sensitivity: 57.1%, specificity: 94.4%). In peripheral blood prior to LEN/PEM, the lower NLR (NLR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
- Department of Pathology, Kagoshima University hospital, Kagoshima, Japan.
- Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
- Course of Advanced Cancer Medicine for Gynecologic Cancer, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
ORCID-Profile: Shintaro Yanazume, Akihide Tanimoto, Hiroaki Kobayashi
Zitieren
APA
Yanazume, S., Kobayashi, Y., Kirita, Y., Kitazono, I., Nagata, C., Kozai, A., Tanimoto, A., & Kobayashi, H. (2025). A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16182
Vancouver
Yanazume S, Kobayashi Y, Kirita Y, Kitazono I, Nagata C, Kozai A, et al. A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.16182
BibTeX
@article{Yanazume2025,
author = {Yanazume, Shintaro and Kobayashi, Yusuke and Kirita, Yukari and Kitazono, Ikumi and Nagata, Chikako and Kozai, Ayumi and Tanimoto, Akihide and Kobayashi, Hiroaki},
title = {A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
doi = {10.1111/jog.16182}
}
EUVIMED